<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35596920</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-6269</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current oncology reports</Title>
          <ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-022-01286-0</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">This review focuses on the feasibility of combining Bruton's tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R/R MCL. Ibrutinib, acalabrutinib, and zanubrutinib are covalent irreversible BTKis approved for R/R MCL. Brexucabtagene autoleucel was the first CAR T-cell therapy approved for R/R MCL based on findings from the ZUMA-2 trial. There is evidence to suggest that combination treatment with BTKis and CAR T-cell therapy may improve CAR T-cell efficacy. As BTKis and CAR T-cell therapy become mainstays in R/R MCL therapy, combination treatment strategies should be evaluated for their potential benefit in R/R MCL.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Munoz</LastName>
            <ForeName>Javier L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic, Phoenix, AZ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yucai</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jain</LastName>
            <ForeName>Preetesh</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Lymphoma-Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. PJain@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Lymphoma-Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Oncol Rep</MedlineTA>
        <NlmUniqueID>100888967</NlmUniqueID>
        <ISSNLinking>1523-3790</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bruton’s tyrosine kinase</Keyword>
        <Keyword MajorTopicYN="N">Chimeric antigen receptor T-cell therapy</Keyword>
        <Keyword MajorTopicYN="N">Combination therapy</Keyword>
        <Keyword MajorTopicYN="N">Relapsed/refractory mantle cell lymphoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>11</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35596920</ArticleId>
        <ArticleId IdType="doi">10.1007/s11912-022-01286-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s11912-022-01286-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <ReferenceList>
          <Title>Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance</Title>
          <Reference>
            <Citation>Jain P, Wang ML. Mantle cell lymphoma—a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638–56.</Citation>
          </Reference>
          <Reference>
            <Citation>Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312–32.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33122850</ArticleId>
              <ArticleId IdType="doi">10.1038/s41375-020-01072-6</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">26059948</ArticleId>
              <ArticleId IdType="pmc">4528064</ArticleId>
              <ArticleId IdType="doi">10.1182/blood-2015-03-635326</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799–803.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">29572505</ArticleId>
              <ArticleId IdType="pmc">6087720</ArticleId>
              <ArticleId IdType="doi">10.1038/s41375-018-0023-2</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33676527</ArticleId>
              <ArticleId IdType="pmc">7937220</ArticleId>
              <ArticleId IdType="doi">10.1186/s13045-021-01049-7</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2(15):2012–9.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30108109</ArticleId>
              <ArticleId IdType="pmc">6093735</ArticleId>
              <ArticleId IdType="doi">10.1182/bloodadvances.2018013060</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">23886836</ArticleId>
              <ArticleId IdType="pmc">3795457</ArticleId>
              <ArticleId IdType="doi">10.1182/blood-2013-06-507947</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">26957112</ArticleId>
              <ArticleId IdType="pmc">4784459</ArticleId>
              <ArticleId IdType="doi">10.1186/s13045-016-0250-9</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. J Med Chem. 2019;62(17):7923–40.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31381333</ArticleId>
              <ArticleId IdType="doi">10.1021/acs.jmedchem.9b00687</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–67.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">29241979</ArticleId>
              <ArticleId IdType="doi">10.1016/S0140-6736(17)33108-2</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022. https://doi.org/10.1182/blood.2021014162 .</Citation>
          </Reference>
          <Reference>
            <Citation>•• Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42 This was the pivotal clinical trial that led to the US FDA approval of brexucabtagene autoleucel for patients with R/R MCL.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32242358</ArticleId>
              <ArticleId IdType="pmc">7731441</ArticleId>
              <ArticleId IdType="doi">10.1056/NEJMoa1914347</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30175400</ArticleId>
              <ArticleId IdType="doi">10.1111/bjh.15567</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33154951</ArticleId>
              <ArticleId IdType="pmc">7116322</ArticleId>
              <ArticleId IdType="doi">10.3389/fonc.2020.591577</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Li X, Chen W. Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol. 2019;26(6):427–33.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31577606</ArticleId>
              <ArticleId IdType="pmc">6791516</ArticleId>
              <ArticleId IdType="doi">10.1097/MOH.0000000000000548</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Fan F, Yoo HJ, Stock S, Wang L, Liu Y, Schubert ML, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419–28.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32683672</ArticleId>
              <ArticleId IdType="doi">10.1002/ijc.33212</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–27.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">26813675</ArticleId>
              <ArticleId IdType="pmc">4778162</ArticleId>
              <ArticleId IdType="doi">10.1182/blood-2015-11-679134</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112(7):2642–51.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33932067</ArticleId>
              <ArticleId IdType="pmc">8253282</ArticleId>
              <ArticleId IdType="doi">10.1111/cas.14915</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T-cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–60.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32076701</ArticleId>
              <ArticleId IdType="pmc">7205814</ArticleId>
              <ArticleId IdType="doi">10.1182/blood.2019002936</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T-cells for mantle cell and follicular lymphomas. Blood Adv. 2020;4(22):5858–62.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33232481</ArticleId>
              <ArticleId IdType="pmc">7686908</ArticleId>
              <ArticleId IdType="doi">10.1182/bloodadvances.2020003391</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother. 2020;43(4):107–20.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31899702</ArticleId>
              <ArticleId IdType="pmc">7144752</ArticleId>
              <ArticleId IdType="doi">10.1097/CJI.0000000000000307</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32552760</ArticleId>
              <ArticleId IdType="pmc">7302387</ArticleId>
              <ArticleId IdType="doi">10.1186/s13045-020-00914-1</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–8.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">26673811</ArticleId>
              <ArticleId IdType="doi">10.1016/S0140-6736(15)00667-4</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang M, Rule S, PL ZI, Goy AH, Casasnovas R-O, Smith SD, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2020;136:38–9.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2020-134824</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33676628</ArticleId>
              <ArticleId IdType="doi">10.1016/S0140-6736(21)00224-5</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang ML, Shah N, Alencar A, Gerson JN, Patel MR, Fakhri B, et al. Pirtobrutinib, a highly selective, non-covalent, (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Blood. 2021;138(Suppl 1):381.</Citation>
          </Reference>
          <Reference>
            <Citation>Mannina D, Loteta B. Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep Hematol. 2017;2017:9583257.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">28791187</ArticleId>
              <ArticleId IdType="pmc">5534293</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, de Kerviler E, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695–8.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">26239089</ArticleId>
              <ArticleId IdType="pmc">4591793</ArticleId>
              <ArticleId IdType="doi">10.1182/blood-2015-05-647834</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol. 2021;11:760405.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">35004280</ArticleId>
              <ArticleId IdType="pmc">8739956</ArticleId>
              <ArticleId IdType="doi">10.3389/fonc.2021.760405</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Estupiňan HY, Berglof A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33777941</ArticleId>
              <ArticleId IdType="pmc">7991787</ArticleId>
              <ArticleId IdType="doi">10.3389/fcell.2021.630942</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Abbas HA, Wierda WG. Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">34055635</ArticleId>
              <ArticleId IdType="pmc">8162209</ArticleId>
              <ArticleId IdType="doi">10.3389/fonc.2021.668162</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–37.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32698195</ArticleId>
              <ArticleId IdType="pmc">7596846</ArticleId>
              <ArticleId IdType="doi">10.1182/blood.2020006449</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835–47.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">28182323</ArticleId>
              <ArticleId IdType="pmc">6152914</ArticleId>
              <ArticleId IdType="doi">10.1111/jth.13651</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–7.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">25138588</ArticleId>
              <ArticleId IdType="doi">10.1038/leu.2014.247</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study. J Clin Oncol. 2021;39(31):3453–62.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">34464154</ArticleId>
              <ArticleId IdType="doi">10.1200/JCO.21.00693</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31558250</ArticleId>
              <ArticleId IdType="doi">10.1016/j.jacc.2019.07.056</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">28832957</ArticleId>
              <ArticleId IdType="pmc">5912680</ArticleId>
              <ArticleId IdType="doi">10.1111/bjh.14870</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>McFarlane T, Rehman N, Wang K, Lee J, Carter C. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Ann Palliat Med. 2020;9(3):1296–306.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31594365</ArticleId>
              <ArticleId IdType="doi">10.21037/apm.2019.08.05</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32731259</ArticleId>
              <ArticleId IdType="pmc">7596850</ArticleId>
              <ArticleId IdType="doi">10.1182/blood.2020006844</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–43 e5.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">28552327</ArticleId>
              <ArticleId IdType="pmc">5571650</ArticleId>
              <ArticleId IdType="doi">10.1016/j.ccell.2017.04.012</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–9.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">29437588</ArticleId>
              <ArticleId IdType="doi">10.1182/blood-2017-11-818286</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Handunetti SM, Sang Tang CP, Nguyen T, Zhou X, Thompson E, Sun H, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood. 2019;134:170.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2019-125488</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Woyach JA, Huang Y, Rogers K, Bhat SA, Grever MR, Lozanski A, et al. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood. 2019;134:504.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2019-127674</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12(1):2877.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">34001881</ArticleId>
              <ArticleId IdType="pmc">8128874</ArticleId>
              <ArticleId IdType="doi">10.1038/s41467-021-22872-z</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">34177947</ArticleId>
              <ArticleId IdType="pmc">8222783</ArticleId>
              <ArticleId IdType="doi">10.3389/fimmu.2021.689472</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NFkappaB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9(2):86.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">29367645</ArticleId>
              <ArticleId IdType="pmc">5833745</ArticleId>
              <ArticleId IdType="doi">10.1038/s41419-017-0157-6</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30680780</ArticleId>
              <ArticleId IdType="doi">10.1002/ajh.25418</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32670869</ArticleId>
              <ArticleId IdType="pmc">7326110</ArticleId>
              <ArticleId IdType="doi">10.3389/fonc.2020.00849</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T-cell therapy in clinical practice for relapsed/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(12):2305–21.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31446199</ArticleId>
              <ArticleId IdType="doi">10.1016/j.bbmt.2019.08.015</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium. Blood. 2021;138. This real-world study showed that brexucabtagene autoleucel can be prescribed as standard of care with similar efficacy and toxicity as compared with the pivotal clinical trial (ZUMA-2) experience.</Citation>
          </Reference>
          <Reference>
            <Citation>Wang M, Munoz J, Goy AH, Locke FL, Jacobson CA, Hill BT, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. Blood. 2020;136:20–2.</Citation>
          </Reference>
          <Reference>
            <Citation>Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend NHL 001. Blood. 2020;136:10–1.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2020-136158</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium. Blood. 2021;138(Suppl 1):744.</Citation>
          </Reference>
          <Reference>
            <Citation>Romancik JT, Goyal S, Gerson JN, Ballard HJ, Sawalha Y, Bond DA, et al. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel. Blood. 2021;138(Suppl 1):1756.</Citation>
          </Reference>
          <Reference>
            <Citation>Romancik JT, Goyal S, Gerson JN, Ballard HJ, Sawalha Y, Bond DA, et al. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel. Blood. 2021;138(Suppl 1):1756.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-153277</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Herbaux G, Bret C, Di Blasi R, Bachy E, Beauvais D, Gat E, et al. Kte-X19 in relapsed or refractory mantle-cell lymphoma, a "real-life" study from the Descar-T Registry and Lysa Group. Blood. 2021;138(Suppl 1):743.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-148626</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T-cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010–20.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">28715249</ArticleId>
              <ArticleId IdType="pmc">5590803</ArticleId>
              <ArticleId IdType="doi">10.1200/JCO.2017.72.8519</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022;139(12):1794–1806.</Citation>
          </Reference>
          <Reference>
            <Citation>ClinicalTrials.gov . Study to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (ZUMA-2). https://clinicaltrials.gov/ct2/show/NCT02601313 . Accessed November 3, 2021.</Citation>
          </Reference>
          <Reference>
            <Citation>• Wang M, Rossi JM, Munoz J, Goy AH, Locke FL, Reagan PM, et al. Pharmacological profile and clinical outcomes of KTE-X19 by prior Bruton tyrosine kinase inhibitor (BTKi) exposure or mantle cell lymphoma (MCL) morphology in patients with relapsed/refractory (R/R) MCL in the ZUMA-2 trial. Blood. 2020;136(Suppl 1):29 This analysis showed that there may be a difference in outcomes depending on which BTKi is chosen as bridging therapy prior to the administration of brexucabtagene autoleucel (KTE-X19).</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2020-136831</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Scarfo I, Gallagher KME, Leick MB, Kann NC, Budka J, Sowirajan B, et al. Effects of prior exposure to Tec kinase (BTK/ITK) inhibitors on Kte-X19 products. Blood. 2021;138:3849.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-146941</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30592986</ArticleId>
              <ArticleId IdType="doi">10.1016/j.bbmt.2018.12.758</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Yanez L, Alarcon A, Sanchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T-cell therapy. ESMO Open. 2020;4(Suppl 4):e000746.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32839196</ArticleId>
              <ArticleId IdType="pmc">7451454</ArticleId>
              <ArticleId IdType="doi">10.1136/esmoopen-2020-000746</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31848460</ArticleId>
              <ArticleId IdType="doi">10.1038/s41571-019-0297-y</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Park JH, Sauter CS, Palomba ML, Shah GL, Dahi PB, Lin RJ, et al. A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T-cell therapy for relapsed or refractory lymphoma. Blood. 2021;138(Suppl 1):96.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-150431</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wong SW, Richard S, Lin Y, Madduri D, Jackson CC, Zudaire E, et al. Anakinra targeting cytokine release syndrome associated with chimeric antigen receptor T-cell therapies. Blood. 2021;138(Suppl 1):2812.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-150592</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Frigault MJ, Gallagher KME, Wehrli M, Valles B, Casey K, Lindell K, et al. A phase II trial of anakinra for prevention of CAR-T-cell mediated neurotoxicity. Blood. 2021;138(Suppl 1):2814.</Citation>
          </Reference>
          <Reference>
            <Citation>Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–26.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30135176</ArticleId>
              <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0442</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Peters FS, Strefford JC, Eldering E, Kater AP. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica. 2021;106(5):1234–43.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">33691381</ArticleId>
              <ArticleId IdType="pmc">8586819</ArticleId>
              <ArticleId IdType="doi">10.3324/haematol.2020.267914</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Adada MM, Sakemura R, Cox MJ, Manriquez-Roman C, Siegler EL, Tapper E, et al. Favorable modulation of chimeric antigen receptor T-cells safety and efficacy by the non-covalent BTK inhibitor vecabrutinib. Blood. 2021;138(Suppl 1):906.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2021-151073</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>ClinicalTrials.gov . Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC). https://clinicaltrials.gov/ct2/show/NCT04234061 . Accessed October 27, 2021.</Citation>
          </Reference>
          <Reference>
            <Citation>ClinicalTrials.gov . A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor(CAR)-T-Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL). https://clinicaltrials.gov/ct2/show/NCT04484012 . Accessed December 20, 2021.</Citation>
          </Reference>
          <Reference>
            <Citation>Romancik JT, Cohen JB. Sequencing of novel therapies for mantle cell lymphoma. Curr Treat Options in Oncol. 2021;22(12):118.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1007/s11864-021-00907-3</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–71.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">30190341</ArticleId>
              <ArticleId IdType="pmc">6355471</ArticleId>
              <ArticleId IdType="doi">10.3324/haematol.2018.198812</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):179.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">34717692</ArticleId>
              <ArticleId IdType="pmc">8556975</ArticleId>
              <ArticleId IdType="doi">10.1186/s13045-021-01188-x</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">32911375</ArticleId>
              <ArticleId IdType="doi">10.1016/j.leukres.2020.106432</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>McLellan AD, Ali Hosseini Rad SM. Chimeric antigen receptor T-cell persistence and memory cell formation. Immunol Cell Biol. 2019;97(7):664–74.</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">31009109</ArticleId>
              <ArticleId IdType="doi">10.1111/imcb.12254</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
